Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Non Operating Income (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Non Operating Income for 3 consecutive years, with -$46000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 212.2% to -$46000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.6 million, a 100.08% decrease, with the full-year FY2024 number at $2.0 billion, up 9947.45% from a year prior.
  • Non Operating Income was -$46000.0 for Q3 2025 at Inhibrx Biosciences, up from -$1.3 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.0 billion in Q2 2024 to a low of -$6.0 million in Q3 2023.
  • A 3-year average of $222.8 million and a median of -$59000.0 in 2024 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: surged 35469.85% in 2024, then tumbled 594.92% in 2025.
  • Inhibrx Biosciences' Non Operating Income stood at -$6.0 million in 2023, then skyrocketed by 102.16% to $129000.0 in 2024, then tumbled by 135.66% to -$46000.0 in 2025.
  • Per Business Quant, the three most recent readings for INBX's Non Operating Income are -$46000.0 (Q3 2025), -$1.3 million (Q2 2025), and -$410000.0 (Q1 2025).